

## **Dr. Mark Heffernan, Chief Executive Officer, Nexvet Biopharma**

---

Dr Heffernan has international leadership in capital raising and commercialisation of novel pharmaceutical products. Since April 2011, Dr Heffernan has been the founding Chief Executive Officer and a member of the board of directors of Nexvet Biopharma plc. The company employs over 50 full time staff in Australia, Ireland and the USA, focused on developing monoclonal antibodies for companion animals. Nexvet has raised over US\$80 million, including \$40m in a NASDAQ public listing in 2015. In April 2017, the world's largest animal health company, Zoetis, announced an acquisition of Nexvet, which is set to complete in Q3 2017.

In 2003, Mark co-founded Opsona Therapeutics Ltd., an Irish biotechnology company focused on human mAbs for inflammatory diseases, where he served as Founder and Chief Executive Officer from January 2004 to March 2011 and as a Director from January 2004 to December 2011. During his time as CEO, he raised over €40 million to commercialise research from Trinity College, Dublin.

Prior to co-founding Opsona, Mark worked in research and business development for the Circadian Group of companies in Melbourne. Mark Heffernan has a B.Sc. (Hons.) in Biochemistry and Pharmacology and a Ph.D. in Biochemistry from Monash University (Australia).

